- Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer Benefit of ...
MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, ...
Galera Therapeutics, a Phase 3 biotech developing treatments for radiotherapy-induced oral mucositis, raised $60 million by offering 5.0 million shares at $12, below the range of $14 to $16. Insiders ...
Galera Therapeutics Inc. set terms for its planned initial public offering on Monday, saying it plans to offer 5 million shares priced at $14 to $16 each. The clinical-stage biotech would raise $80 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback